Heteronuclear dual-metal atom catalysts for nanocatalytic tumor therapy

Han, Jingyi; Guan, Jingqi

doi:10.1016/s1872-2067(22)64207-4

Cited by 22 publications

(5 citation statements)

References 242 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with SACs, the active sites of DACs increase due to the increase in the metal loadings. 122 In addition, the interaction between homonuclear metals can regulate the electronic structure of active centers, which is conducive to reducing the reaction energy barrier. Zhou et al constructed a diatomic Ag/graphene with AgN 3 –AgN 3 structure (Ag 2 –G), which showed good activity in catalysing the conversion of CO 2 to CO, with an FE of up to 93.4%.…”

Section: Reasonable Control Of the Geometric And Electronic Structure...mentioning

confidence: 99%

Structural engineering of atomic catalysts for electrocatalysis

Tang,

Bai,

Wang

et al. 2024

Chem. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Reasonable Control Of the Geometric And Electronic Structure...mentioning

confidence: 99%

Structural engineering of atomic catalysts for electrocatalysis

Tang,

Bai,

Wang

et al. 2024

Chem. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[20] Specifically, substantially enhanced therapeutic efficacy and bio-safety compared to conventional treatment protocols can be readily achieved through elevating the focus-localized catalytic activity of nano-catalysts by catalytic nanomaterial design and surface modification, targeted delivery and stimulus-responsive-controlled releases of key species. [21] This makes catalysis-based nanomedicine an emerging interdisciplinary field with great prospects, and is of great significance to the advancement of biomedical detection and disease treatments.…”

Section: Nanocatalytic Immunomodulation Triggered By the Specific Mic...mentioning

confidence: 99%

Nanocatalytic Anti‐Tumor Immune Regulation

Li,

Jiang,

et al. 2024

Angewandte Chemie

View full text Add to dashboard Cite

Immunotherapy has brought a new dawn for human being to defeat cancer. Although existing immunotherapy regimens (CAR‐T, etc.) have made breakthroughs in the treatments of hematological cancer and few solid tumors such as melanoma, the therapeutic efficacy on most solid tumors is still far from being satisfactory. In recent years, the researches on tumor immunotherapy based on nanocatalytic materials are under rapid development, and significant progresses have been made. Nanocatalytic medicine has been demonstrated to be capable of overcoming the limitations of current clinicnal treatments by using toxic chemodrugs, and exhibits highly attractive advantages over traditional therapies, such as the enhanced and sustained therapeutic efficacy based on the durable catalytic activity, remarkably reduced harmful side‐effects without using traditional toxic chemodrugs, and so on. Most recently, nanocatalytic medicine has been introduced in the immune‐regulation for disease treatments, especially, in the immunoactivation for tumor therapies. This article presents the most recent progresses in immune‐response activations by nanocatalytic medicine‐initiated chemical reactions for tumor immunotherapy, and elucidates the mechanism of nanocatalytic medicines in regulating anti‐tumor immunity. By reviewing the current research progress in the emerging field, this review will further highlight the great potentials and broad prospects of nanocatalysis‐based anti‐tumor immune‐therapeutics.

show abstract

“…According to the types of metals, DACs are mainly divided into homologous binuclear and heterologous binuclear metals. 210–212…”

Section: Categories Of Catalysts For Eco2rrmentioning

confidence: 99%